Tim Barrow-Williams

Achieve High Virus Titers In Your AAV Development Whether you're working with Sf-9 insect cells or human HEK/293 cells in your AAV production, look to our expertise in media to quickly maximize your virus titers. Extensively tested, our media allow you to achieve your productivity objectives. Experience the benefits of our optimized cell culture media for yourself—click here to request your free sample and test it on your cells.

Achieving a successful CGT involves integrating delivery technologies with modular manufacturing platforms and rigorous quality control systems to ensure safety, efficacy, and scalability. But more needs to be done for CGTs to become widely accessible and have an even greater long-lasting impact on the healthcare ecosystem.

By Paolo Siciliano, Gloria Lam, Geoffrey Uhl, and Tim Barrow-Williams, PA Consulting Across the world, a surge of new cell and gene therapies (CGTs) are reaching commercial approval. Achieving a successful CGT involves integrating delivery technologies with modular manufacturing platforms and rigorous quality control systems to ensure safety, efficacy, and scalability.